Vantedge Medical Completes Acquisition of Hobson & Motzer

The partnership with Hobson enhances Vantedge Medical's consumables platform and broadens the company's technical capabilities, customer base and geographical footprint

Vantedge Medical (“Vantedge”), a portfolio company of Aterian Investment Partners (“Aterian”), is pleased to announce the acquisition of Hobson & Motzer, Inc. (“Hobson” or the “Company”).

Founded in 1912 and based in Connecticut, Hobson is a manufacturer of precision medical devices for the global surgical stapler market. 100% of Hobson’s sales stream is derived from medical consumables devices. The Company’s facilities are highly automated and house a broad set of capabilities including progressive stamping, precision electrochemical machining, coined wire as well as leading tool and die capabilities. Hobson represents the fifth medical technology add-on acquisition for Vantedge since 2018.

The acquisition of Hobson further strengthens Vantedge’s position as a nationwide manufacturing partner to blue-chip medical OEMs and broadens Vantedge’s consumable portfolio offering. Since Aterian’s acquisition of Vantedge in May 2018, Vantedge has acquired five medical technology businesses, established and fully commercialized new production facilities, completed substantial capital equipment capacity expansion and significantly invested in human capital throughout the organization. Vantedge now operates nine facilities across the United States with more than 1,200 employees.

“It gives me great pleasure to announce the union of Vantedge Medical and Hobson & Motzer. I have worked with the Hobson & Motzer team for many years, and they consistently delivered best-in-class quality, service, value, and innovation. Their depth and scale of capabilities, backed by over 100 years of experience, perfectly complements the existing Vantedge capabilities, enhances the value we bring to the world’s leading medical technology companies, and amplifies the difference we are making in the lives of patients and their families.”, commented Brian King, Vantedge Medical, Chairman & CEO.

Greg Santorno, Vantedge Medical’s Chief Commercial Officer mentioned, “Our union with Hobson & Motzer provides an expanded capability set that significantly increases the value we will deliver to our customers. Providing additional device content enables supply chain simplification, risk reduction, collaborative innovation, and accelerated time to market. The addition of precision progressive die stamping, unique value-add machining and assembly technologies, and a deep expertise in the manufacturing of surgical stapler anvils, complements our existing strengths serving the Robotic Assisted Surgery, Surgical Instrumentation, Orthopedics, Ophthalmology, Dental, Drug Delivery and Medical Diagnostics markets.”

“As I contemplated transitioning the company to new ownership, my key requirements were to find a company that shared our commitment to quality, service and innovation, had deep experience in the MedTech space and viewed our capabilities as enablers for growth. Vantedge Medical met these criteria in every way. I look forward to the continuing legacy of performance and market leadership, just at a much larger scale.”, added Bruce Dworak, President / Owner, Hobson & Motzer.

“We are excited to share the news about this transaction which we believe allows Vantedge to take the next significant step in its strategic development. Vantedge continues to evolve as a differentiated, scaled and expanding Medical Technology supplier into the industry’s most attractive OEMs across a variety of manufacturing disciplines and treatment modalities. The human health technologies that Vantedge serves on behalf of its’ customers change lives for the better, and in certain circumstances, save them. It is a privilege to wake up every day and work alongside Vantedge, and through Vantedge, our customers.”, said Brandon Bethea, Co-Founder & Partner, Aterian Investment Partners.

Weil Gotshal & Manges LLP advised Aterian on the legal aspects of this transaction.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version